載入中
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
前收盤價
US$2.26
−US$0.04 · -1.74%
盤後
US$2.26
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
日內區間
目前US$2.26
52週區間
目前US$2.26
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
85
深度低估
情緒
58
多空交錯
風險
55
風險偏高
動能
71
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
日內區間
目前US$2.26
52週區間
目前US$2.26
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.06億 USD | 1.8億 USD | 1.56億 USD | 1.62億 USD | 1.31億 USD |
| 銷貨成本 | 9384.5萬 USD | 8074.8萬 USD | 6996.7萬 USD | 7495.4萬 USD | 6347.5萬 USD |
| 毛利 | 1.12億 USD | 9952.2萬 USD | 8640萬 USD | 8709.4萬 USD | 6738.4萬 USD |
| 研究與開發 | 6772萬 USD | 5890.7萬 USD | 6763.9萬 USD | 6410.7萬 USD | 6369.1萬 USD |
| 銷售、一般及管理費用 | 8091.4萬 USD | 7589.1萬 USD | 7551.6萬 USD | 8333.5萬 USD | 8128.8萬 USD |
| 營業費用 | 1.21億 USD | 1.14億 USD | 1.16億 USD | 1.21億 USD | 1.16億 USD |
| 利息支出 | 834.3萬 USD | 887.7萬 USD | 838.6萬 USD | 583.1萬 USD | 492.3萬 USD |
| 折舊和攤銷 | 142.6萬 USD | 185.5萬 USD | 259.9萬 USD | 298.4萬 USD | 314.8萬 USD |
| 營業利益 | −868.1萬 USD | −1422.5萬 USD | −3005.3萬 USD | −3408.1萬 USD | −4893.6萬 USD |
| 淨利 | −1562.7萬 USD | −2091.8萬 USD | −3748.9萬 USD | −4277.9萬 USD | −5437.4萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 76.99%報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK1997.81萬0.30%79.17億 USD0.75%US$88.02-1.79%
ARK Genomic Revolution ETFARKG1768.19萬0.83%22.19億 USD0.75%US$49.48-3.55%
Vanguard Morningstar Total Stock Market ETFVTI1603.95萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1208.35萬0.02%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF615.99萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO415.32萬0.03%139.17億 USD0.24%US$353.71-0.86%
Fidelity Enhanced Small Cap ETFFESM397.45萬0.06%64.1億 USD0.28%US$45.24-0.48%
Vanguard Russell 2000 ETFVTWO301.7萬0.02%180億 USD0.06%US$112.27-0.35%ARK Innovation ETFARKKARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
